DarioHealth stock heads into Q3 results after board change

DarioHealth Corp. is due to report its third-quarter 2026 results on Thursday, November 12, after the company announced the reporting date on November 2. The notice on the DarioHealth investor website puts the quarterly update at the center of the next trading session.

Chairman change raises strategic focus

DarioHealth named veteran healthcare executive John R. Palumbo chairman of the board on November 4. The company said the appointment supports its positioning at the convergence of consumer and payer-funded care, adding a governance development to the earnings setup.

The company is also highlighting its expansion beyond direct-to-consumer diabetes management. Its investor materials describe a business-to-business-to-consumer model serving employers, insurers and other healthcare organizations, with digital programs covering metabolic, musculoskeletal and behavioral health conditions.

Recurring revenue remains in focus

DarioHealth says its platform combines digital engagement, clinical intervention and connected devices such as glucose meters, blood-pressure cuffs and scales. The company also reports approximately 13 million US dollars in contracted and late-stage annual recurring revenue, with more than 80 percent tied to multi-condition offerings and revenue contributions expected in 2026 and 2027.

The scheduled results should give investors a fresh view of revenue progress, operating costs and cash use as DarioHealth seeks to scale its payer and provider relationships. The company is headquartered in the United States and operates across the United States, Canada, the European Union, Australia and New Zealand.

Broader investor sentiment in US equities remains a backdrop for digital-health shares, with the S&P 500 serving as the main US market reference.

More news and analyses on DarioHealth stock